BioMarin Pharmaceutical Inc.'s recent financial performance aligns with several key metrics and insights from InvestingPro. The company's revenue growth of 15.83% over the last twelve months, as reported by InvestingPro, supports the strong Q3 results mentioned in the article. The quarterly revenue growth of 19.61% in Q2 2024 indicates a consistent upward trend, which is reflected in BioMarin's updated full-year guidance.